Fig 1. Susceptibility of planktonic S. aureus (MRSA) to beta and “short and long-lived” alpha radiation measured by CFU/ml for survivability (A,C,E) and XTT reduction assay for the metabolic activity (B,D,F).

Increasing doses of RIT with specific anti-WTA 4497 antibodies and non-specific antibodies Palivizumab labeled with ¹⁷⁷Lu (A,B), ²²⁵Ac (C,D) and ²¹³Bi (E,F). Treatment results were compared to unlabeled 4497 mAb,Palivizumab, and iodine controls. Each data point represents the average of two measurements.